Arcturus Therapeutics Holdings Inc. (ARCT) Financial Analysis & Valuation | Quarter Chart
Arcturus Therapeutics Holdings Inc. (ARCT)
ARCTPrice: $8.67
Fair Value: 🔒
🔒score
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) defi... more
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccine... more
Description
Shares
| Market Cap | $235.43M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Joseph E. Payne |
| IPO Date | 2013-05-22 | CAGR | — |
| Employees | 174 | Website | arcturusrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ARCT chart loading...
Fundamentals
Technicals
| Enterprise Value | $179.41M | P/E Ratio | -3.93 |
| Forward P/E | -2.1 | PEG Ratio | — |
| P/S Ratio | 2 | P/B Ratio | 1.02 |
| P/CF Ratio | -40.7 | P/FCF Ratio | -3.64 |
| EPS | $-2.22 | EPS Growth 1Y | 35.16% |
| EPS Growth 3Y | -55.76% | EPS Growth 5Y | -15.17% |
| Revenue Growth 1Y | -35.39% | Gross Margin | 0.45% |
| Operating Margin | -0.62% | Profit Margin | -0.51% |
| ROE | -0.25% | ROA | -0.19% |
| ROCE | -0.28% | Current Ratio | 5.9 |
| Quick Ratio | 5.9 | Cash Ratio | 4.22 |
| Debt/Equity | 0.1 | Interest Coverage | — |
| Altman Z Score | 0.59 | Piotroski Score | 2 |